Urine Metabolites in the Diagnosis of Disease
Condition(s) studied
Study summary
The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.
This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease.
The main questions it aims to answer are:
1. Does the platform identify a disease signal within each disease cohort, compared to normal controls?
2. How well does the test perform (e.g. sensitivity and specificity/false-positive rate)?
Eligibility
Primary outcome measure(s)
- Disease signal detection — From date of enrollment to the end of sample analysis, up to 100 weeks
Disease signal detection quantification within each disease cohort, compared to normal controls. - Test performance measures — From date of enrollment to the end of sample analysis, up to 100 weeks
Sensitivity and specificity/false-positive rate
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Unio Health Partners (Gastroenterology) | Encinitas | California | Recruiting |
| Digestive Health Associates | Santa Monica | California | Recruiting |
| Westside Gastro Care | Santa Monica | California | Recruiting |
| Bass Medical Group (Gastroenterology) | Walnut Creek | California | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06710067 on ClinicalTrials.gov ↗ ← All trials in the USA